Oculis

General Information

Company Name

Oculis

Founded Year

2017

Location (Offices)

Lausanne, Switzerland +3

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Health Care, Pharmaceutical

Funding Stage

Post Ipo Equity

Social Media

Oculis - Company Profile

Oculis is a biopharmaceutical company focused on developing eye drops to treat ophthalmic diseases, with the aim of enhancing the lives of patients globally. The company's highly differentiated pipeline includes innovative product candidates such as OCS-01 for diabetic macular edema (DME) and post-cataract surgery inflammation and pain, OCS-02 (licaminlimab) for dry eye disease (DED) and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis (AON). Founded in 2017, Oculis is headquartered in Switzerland, with operations in the U.S. and Iceland. The company received a $59.00M Post-IPO Equity investment on 11 April 2024. Oculis is backed by leading international healthcare investors and is led by an experienced management team, with a successful track record. For more information, please visit: www.oculis.com.

Taxonomy: ophthalmology, biopharmaceuticals, drug delivery, topical eye drops, ophthalmic diseases, innovative product candidates, diabetic macular edema, inflammation and pain, dry eye disease, anterior uveitis, neuroprotective, optic neuritis, international healthcare investors, non-invasive treatment, posterior eye diseases

Funding Rounds & Investors of Oculis (13)

View All

Funding Stage	Amount	No. Investors	Investors	Date
Post-IPO Equity	$59.00M	-		11 Apr 2024
Post-IPO Equity	$40.25M	-		01 Jun 2023
Post-IPO Equity	$91.00M	5	Tekla Capital Management	03 Mar 2023
Series C	$57.00M	10	Tekla Capital Management	04 May 2021
Series B	Fr.15.50M	3	Tekla Capital Management	04 Jan 2019